The screening of novel compounds to predict potential toxicity to the hematopoietic system (i.e., hematotoxicity) is an important step in drug development. This webinar discusses the importance of hematotoxicity testing in drug development, reviews methods for in vitro assay standardization, and explores the use of both colony-forming unit (CFU) assays and lineage-specific liquid culture-based assays as tools for in vitro drug screening.
To view the webinar, please complete the form, or sign in to your account.
StemCell Technologies Inc. and affiliates ("STEMCELL Technologies") does not share your email address with third parties. StemCell Technologies Inc. will use your email address to confirm your identity and send you newsletters, transaction-related emails, promotional and customer service emails in accordance with our privacy policy. You can change your email preferences at any time.